To the full analysis
Apotex Health stock: growth
APTX.TOApotex Health reported $2.45B in revenue for fiscal 2025, up 4.2% on the prior year.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9%
per year from 2023 to 2025, per share 8.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
0%
per year from 2023 to 2025, per share −0.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2023 | |
|---|---|
| Revenue | 9.0% |
| Revenue per share | 8.2% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | 0.0% |
| Free cash flow per share | −0.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2023 | $2.06B | −$103.11M | $322.4M |
| 2024 | $2.35B | $106.47M | $217.79M |
| 2025 | $2.45B | $262.32M | $322.12M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CA$1.4249)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.